Compare FIZZ & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIZZ | KOD |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 1994 | 2018 |
| Metric | FIZZ | KOD |
|---|---|---|
| Price | $34.41 | $42.35 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $35.00 | ★ $35.43 |
| AVG Volume (30 Days) | 162.8K | ★ 692.0K |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.29 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $1,201,354,000.00 | N/A |
| Revenue This Year | $0.14 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $22.31 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $31.21 | $3.33 |
| 52 Week High | $47.88 | $47.84 |
| Indicator | FIZZ | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 54.05 |
| Support Level | $32.58 | $39.37 |
| Resistance Level | $35.86 | $46.72 |
| Average True Range (ATR) | 0.73 | 3.05 |
| MACD | 0.09 | -0.81 |
| Stochastic Oscillator | 64.09 | 35.41 |
National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.